
|Articles|April 26, 2004
Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes
One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
Study maps thermal dynamics of glaucoma laser treatments
4
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
5














































.png)


